<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03369327</url>
  </required_header>
  <id_info>
    <org_study_id>95-04-159-34058</org_study_id>
    <nct_id>NCT03369327</nct_id>
  </id_info>
  <brief_title>Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus</brief_title>
  <acronym>HIV200</acronym>
  <official_title>Efficacy of a Fixed-Dose Combination Pill of Sofosbuvir and Daclatasvir in Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RojanPharma Pharmaceutical Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a multi-center study 200 patients co-infected with hepatitis C virus (HCV) and human
      immunodeficiency virus (HIV) will be treated with a fixed-dose combination pill combined of
      400 mg sofosbuvir and 30, 60, or 90 mg of daclatasvir - depending on the particular
      antiretroviral treatment (ART) being used by the patient. The treatment duration will be 12
      weeks for subjects without cirrhosis and 24 weeks for those with cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To achieve the goal of elimination of hepatitis C in 2030 as set forward by the world health
      organization (WHO) a main group requiring treatment are subjects co-infected with HIV. These
      subjects offer a particular challenge as they are receiving ART which frequently interferes
      with hepatitis treatment. The number of pills they are already taking also limits the
      compliance of these patients.

      In order to evaluate the efficacy of a fixed-dose combination pill combined of 400 mg
      sofosbuvir and 30, 60, or 90 mg of daclatasvir - depending on the particular ART medicine
      being used by the patient - a multi-center study of 200 co-infected patients has been
      designed.

      The treatment duration will be 12 weeks for subjects without cirrhosis and 24 weeks for those
      with cirrhosis.

      The study is one of the pilots being run for hepatitis C elimination in Iran.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">December 1, 2018</completion_date>
  <primary_completion_date type="Actual">September 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The sustained viral response rate</measure>
    <time_frame>12 weeks after end of treatment</time_frame>
    <description>Qualitative hepatitis C virus RNA polymerase chain reaction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse drug events</measure>
    <time_frame>weeks 2, 4, 8, 12 and 24</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">232</enrollment>
  <condition>Hepatitis C Virus Infection, Response to Therapy of</condition>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>sofosbuvir/daclatasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily fixed-dose combination pill of sofosbuvir and daclatasvir for 12 weeks if the patient is non cirrhotic and for 24 weeks if cirrhotic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sofosbuvir and daclatasvir</intervention_name>
    <description>Depending on the ART received by each patient one of the fixed-dose combination pills below will be used:
Daclatasvir 30 mg and sofosbuvir 400 mg
Daclatasvir 60 mg and sofosbuvir 400 mg
Daclatasvir 90 mg and sofosbuvir 400 mg</description>
    <arm_group_label>sofosbuvir/daclatasvir</arm_group_label>
    <other_name>Sovodak 30/400</other_name>
    <other_name>Sovodak 60/400</other_name>
    <other_name>Sovodak 90/400</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive qualitative hepatitis C virus RNA test on two occasions at least 6 months
             apart

          -  Positive human immunodeficiency virus test

        Exclusion Criteria:

          -  Heart rate &lt; 50/min,

          -  Taking amiodarone

          -  Renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Malekzadeh</last_name>
    <role>Study Chair</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shariati Hospital</name>
      <address>
        <city>Tehran</city>
        <zip>14117</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emam Hospital</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>December 6, 2017</study_first_submitted>
  <study_first_submitted_qc>December 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2017</study_first_posted>
  <last_update_submitted>February 19, 2019</last_update_submitted>
  <last_update_submitted_qc>February 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

